[¹⁸F]Fluorthanatrace ([¹⁸F]FTT)

[¹⁸F]Fluorthanatrace  ([¹⁸F]FTT) is a PET labeled PARP inhibitor analog which provides quantitative images of regional PARP expression and can be an important complement to genomic assays currently used to select patients who will benefit from  PARPi. [¹⁸F]FTT can measure the presence or absence of PARP-1, and as such, can serve as a PARPi companion diagnostic to identify those most likely to respond to PARPi therapy, and importantly, those unlikely to respond. One of the major strengths of Trevarx is the network of academic collaborators located at world class cancer institutions like University of Pennsylvania, MD Anderson Cancer Center, Washington University at St. Louis, University of Washington and others. Early clinical trial data in ovarian and breast cancer research carried out at the numerous institutions support the accuracy of [¹⁸F]FTT tumor uptake as an in-vivo measure of regional PARP-1 drug binding and indicate its potential as a more effective PARPi imaging predictive biomarker than currently used HRD genomics-based assays. 

[¹⁸F]FTT has a rapidly emerging body of published academic research by our academic collaborators, representing a 2-3 year lead over other competitive PET PARPi imaging agents that have only recently completed first-in-human studies.   A Phase 2 multi-center trial in breast cancer under a Trevarx sponsored IND will start in Spring 2022, led by MD Anderson Cancer Center with participation by the University of Pennsylvania and Washington University at St. Louis. Trevarx is developing the validated GMP synthesis and testing for [¹⁸F]FTT that is required to support commercial production for Phase 3 multi-center trials and NDA submission and prompt clinical rollout after drug approval, enabling better guidance of PARPi treatment for cancer patients.

[¹⁸F]FTT Publications